EyePoint Pharmaceuticals Inc (NAS:EYPT)
$ 11.12 -0.03 (-0.27%) Market Cap: 579.18 Mil Enterprise Value: 286.54 Mil PE Ratio: 0 PB Ratio: 2.22 GF Score: 55/100

Q4 2019 EyePoint Pharmaceuticals Inc Earnings Call Transcript

Mar 05, 2020 / 01:30PM GMT
Release Date Price: $13.1 (-9.03%)
Operator

Good morning. My name is Sarah, and I'll be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Fourth Quarter and Full Year 2019 Financial Results Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

I would like to turn the call over to George Elston, Chief Financial Officer and Head of Corporate Development of EyePoint Pharmaceuticals. Sir, you may begin.

George O. Elston
EyePoint Pharmaceuticals, Inc. - CFO & Head of Corporate Development

Thank you, Sarah, and thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals' fourth quarter and full year 2019 financial results and recent corporate developments.

With me today is Nancy Lurker, EyePoint's President and Chief Executive Officer; and Scott Jones, our Chief Commercial Officer. Nancy will provide a corporate overview as well as highlight recent pipeline developments, and Scott will comment on recent progress made on our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot